

Instructions for Use LOVENOX 40mg® (enoxaparin sodium): Administration with safety device



1 Patients should be sitting or lying down and LOVENOX® (enoxaparin sodium) injection administered by sub-cutaneous injection. Select an area on the right or left side of your abdomen at least 5cm from your belly button.

Remember: Do not inject yourself within 5cm (2 ins) of your belly button or near scars or bruises. Clean the area you have selected for your injection if recommended by your doctor. Allow to dry.



2 Carefully remove the needle cap by firmly pulling it straight off the syringe and discard.



3 Gently pinch the cleansed area of the abdomen between your thumb and index finger to make a fold in the skin. Introduce the full length of the needle at a 90° angle into the skin fold held between the thumb and forefinger; inject using standard technique, pushing the plunger to the bottom of the syringe. The skin fold should be held throughout the injection. To minimize bruising, do not rub the injection site after completion of the injection.




4 Remove the needle from the injection site, keeping your finger on the plunger. During this step you can release pressure on the plunger.



5 Pointing the needle away from you and others, activate the LOVENOX® (enoxaparin sodium) safety device by firmly pushing the plunger. The protective sleeve will automatically cover the needle, and an audible “click” will confirm shield activation.



6 Immediately dispose of the syringe in the nearest sharps collector



Minimum Product Information

CLEXANE[®] and CLEXANE FORTE^{*} (enoxaparin sodium)

Indications: Prevention of thrombo-embolic disorders of venous origin in orthopaedic and general surgery. Prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. Prevention of thrombosis in extracorporeal circulation during haemodialysis. Treatment of established DVT. Treatment of unstable angina and non-Q-wave MI, administered with aspirin. **Dosage:** Prophylaxis of venous thromboembolism in (a) high risk surgical patients 40mg/day SC, (b) moderate risk surgical patients 20mg/day SC (c) prolonged thromboprophylaxis (hip replacement) 40mg/day SC for 30 days, (d) medical patients: 40mg/day SC for 6-14 days. Haemodialysis: 0.5-1mg/kg into arterial line at session start, add 0.5-1mg/kg if needed. Treatment of DVT: 1.5mg/kg/day or 1mg/kg/twice daily SC add warfarin within 72 hrs. Unstable angina and non-Q-wave MI: 1mg/kg/12 hrs SC with 100-325mg oral aspirin, for 2-8 days. **Contraindications:** Allergy to Clexane, heparin or its derivatives; acute bacterial endocarditis; high risk of uncontrolled haemorrhage, including haemorrhagic stroke. **Precautions:** Low molecular weight heparins are not interchangeable; do not administer IM; pregnancy; history of heparin-induced thrombocytopenia or gastrointestinal ulceration; hepatic insufficiency; uncontrolled arterial hypertension; impaired haemostasis; recent neuro- or ophthalmologic surgery or ischaemic stroke; recent (12-24 hours) spinal/epidural anaesthesia; diabetic retinopathy; haemorrhage; renal impairment; low weight; transmural MI being treated by thrombolytics; other agents affecting haemostasis; prosthetic heart valves; lactation. Use in Children: The safety and efficacy of enoxaparin sodium in children has not been established*.

Adverse Reactions: Haemorrhage, including potentially fatal haemorrhage; thrombocytopenia; increased liver enzymes or platelet count; neuroaxial haematoma after spinal/epidural anaesthesia or post operative indwelling catheter; injection site reactions; allergic reactions; other.

Please review full product information before prescribing. Full product information available from sanofi-aventis australia pty ltd, 12-24 Talavera Road, Macquarie Park, NSW 2113, ABN 31 008 558 807.

*Subsequent references to "CLEXANE" refer to both CLEXANE and CLEXANE FORTE, [®] Registered Trademark.

Date of preparation: December 2007

* Please note change in Product Information

AU.ENO.08.09.006

sanofi-aventis australia
Talavera Corporate Centre Building
D12-24 Talavera Road, Macquarie Park, NSW 2113
Tel: (+61) 02 8666 2000

